We’re proud to share that Kuano has been featured in GeneOnline’s latest article on the growing impact of quantum computing in life sciences. The piece explores how quantum approaches are advancing drug discovery, and highlights Kuano as a leading innovator in the field.
Read the full article: Unlocking the Potential of Quantum Computing (GeneOnline).
Our platform combines quantum simulations, AI and insights into enzyme structure to guide the design of potent and selective drug candidates. Understanding molecular mechanisms can also help identify design strategies to address drug resistance. It’s not just theoretical: our patented technology is already delivering high-value molecules.
Why Kuano?
- Quantum-native expertise: built on deep scientific foundations
- Patented precision: delivering a new level of accuracy in drug discovery
- Fully operational platform: in-house programmes are already in motion
And we’re going beyond enzymes, too, with quantum-enhanced tools such as covalent inhibitor reactivity prediction expanding what’s possible in small-molecule design.
Where we’re focused
We’re advancing internal drug discovery programmes in:
- Oncology and immuno-oncology
- Epigenetics and neurodegeneration
- Challenging target classes, including phosphatases
We’re also working with partners to co-develop the next generation of enzyme inhibitors for proven targets.
Curious to learn more? Let’s talk. Reach us at contact@kuano.ai.
The future of medicine is quantum-powered, and Kuano is making it real.